文献速递淋巴瘤白血病MDS 与骨髓增殖性肿瘤

儿童霍奇金淋巴瘤治疗后继发恶性肿瘤:儿童肿瘤协作组报告

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group.
PubMed 文献 · Blood · 2021-01-01

该研究基于儿童肿瘤协作组AHOD0031试验,评估1711例中危霍奇金淋巴瘤患儿接受应答调整治疗后的继发恶性肿瘤(SMN)风险。

要点

  • 中位随访7.3年,10年SMN累积发生率为1.3%(95%CI 0.6-2.0)。
  • SMN标准化发病比9.5(95%CI 4.5-15.2),绝对超额风险1.2/1000人年。

核心结论

  • 儿童中危霍奇金淋巴瘤幸存者SMN风险增高,放疗与SMN风险增加相关,未来治疗应避免放疗而不牺牲疾病控制。

研究设计与样本

  • 儿童肿瘤协作组AHOD0031研究纳入1711例中危霍奇金淋巴瘤患儿,接受4周期化疗(多柔比星、博来霉素、长春新碱、依托泊苷、泼尼松、环磷酰胺)联合或不联合受累野放疗。
  • 对初始化疗反应缓慢者随机接受额外2周期地塞米松、依托泊苷、顺铂和阿糖胞苷或无额外化疗,所有患者均接受放疗。
  • 中位随访7.3年,分析继发恶性肿瘤(SMN)的发生情况。

主要发现

  • 10年SMN累积发生率为1.3%(95%CI 0.6-2.0)。
  • SMN包括3例急性髓系白血病、11例实体瘤和3例非霍奇金淋巴瘤。
  • SMN标准化发病比为9.5(95%CI 4.5-15.2),绝对超额风险为1.2/1000人年。

临床怎么用

  • 儿童霍奇金淋巴瘤治疗应尽量在保证疾病控制的前提下避免放疗,以降低继发恶性肿瘤风险。
  • 对接受过联合模式治疗(尤其是含放疗)的幸存者需长期监测继发肿瘤,包括白血病、MDS及实体瘤。

局限性

  • 中位随访7.3年,可能已捕获全部继发白血病和MDS,但实体瘤风险需更长随访确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Survivors of Hodgkin lymphoma (HL) have an increased risk of subsequent malignant neoplasms (SMNs). Response-adapted treatment may decrease this risk by reducing exposure to therapy associated with SMN risk. The Children's Oncology Group study AHOD0031 evaluated response-adapted therapy for children and adolescents with intermediate-risk HL. We report the SMNs among 1711 patients enrolled in AHOD0031. Patients were treated with 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide with or without involved-field radiation therapy (RT). Patients with a slow early response to initial chemotherapy were randomized to 2 additional cycles of dexamethasone, etoposide, cisplatin and cytarabine or no additional chemotherapy, and all received RT. At a median follow-up of 7.3 years, an analysis of SMNs was performed. The 10-year cumulative incidence of SMN was 1.3% (95% confidence interval [CI], 0.6-2.0). SMNs included 3 patients with acute myeloid leukemia (AML), 11 with solid tumors, and 3 with non-Hodgkin lymphoma. Sixteen of 17 patients with an SMN had received combined modality therapy. The standardized incidence ratio for SMN was 9.5 (95% CI, 4.5-15.2) with an excess absolute risk of 1.2 per 1000 person-years. The cumulative incidence of SMNs was higher among patients who received RT (P = .037). In multivariate analysis, RT, B symptoms, and race were associated with SMN risk. Given the latency from exposure, we have likely captured all cases of secondary leukemia and myelodysplastic syndrome (MDS). Longer follow-up is needed to determine the risk of solid tumors. Avoidance of RT without sacrificing disease control should remain a goal for future therapeutic approaches. This trial was registered at www.clinicaltrials.gov as #NCT00025259.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Giulino-Roth L, Pei Q, Buxton A, et al. Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group. Blood. 2021. PMID: 33512412. doi:10.1182/blood.2020007225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。